Orlistat
A Proof of Concept Trial in Overweight and Obese Patients, Investigating Effect of EMP16-02 on Body Weight (Primary)
Empros Pharma AB · Phase 1/2 · Completed · Enrollment 156
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| EMP16-02 120 mg orlistat/40 mg acarbose | Obesity or overweight | 40 mg | 26 | n/r | n/r |
| EMP16-02 150 mg orlistat/50 mg acarbose | Obesity or overweight | 50 mg | 26 | n/r | n/r |
| Placebo | Obesity or overweight | n/r | 26 | n/r | n/r |